In an interview on CNBC's Mad Money, Zoetis CEO Juan Ramon Alaix said: "Diagnostics are more important in animals than humans... We are doing very well in China... China is the third largest country for us... Apoquel is treating allergic reactions in dogs and it's doing very well."

In an interview on CNBC's Mad Money, Johnson & Johnson CEO Alex Gorsky said: "We ended 2018 with great results... We could not be more proud of Esketamine... One of the most exciting parts of my job is seeing technology being integrated with healthcare... Less than 5% of surgeries are performed by a robot, we think that can be greater."

According to a post on the FDA's website, Biohaven Pharmaceutical's treatment of multiple system atrophy was granted orphan designation. Reference Link

According to a post on the FDA's website, Amgen's treatment of Acute Myeloid Leukemia was granted orphan designation. Reference Link

Celanese will increase list and off-list selling prices for the following acetyl intermediates products. The price increases are CNY550/MT for Acetic Acid, CNY300/MT for Vinyl Acetate Monomer, CNY575/MT for Acetic Anhydride, and CNY100/MT for Vinyl Acetate-based Emulsions.

This is the lowest level of holdings since December 31, 2018.

Mondelez International, Inc. announced its intention to transfer the securities exchange listing for its notes listed below from the New York Stock Exchange to the Nasdaq Bond Exchange effective February 25, 2019 after market close. The debt securities are expected to begin trading on the Nasdaq Bond Exchange on February 26, 2019.

In a regulatory filing, Fabrinet CFO Toh-Seng Ng disclosed a February 14th-15th sale of 20K shares of common stock at an average price of $54.73 per share. The total transaction size was $1.09M.

In a regulatory 8K filing, Oracle states that on February 12th, its board authorized the repurchase of up to an additional $12.0 billion of common stock under an existing share repurchase program. The stock repurchase authorization does not have an expiration date and the pace of repurchase activity will depend on factors such as Oracle's working capital needs, cash requirements for acquisitions and dividend payments, debt repayment obligations or repurchases of Oracle's debt, Oracle's stock price, and economic and market conditions.

Star Bulk Carriers announced that, pursuant to the company's previously announced share repurchase program, the company purchased today 95,605 of its common shares in open market transactions at an average price of $8.1937 for aggregate consideration of $783,359. The company shall cancel all the common shares it has repurchased.

Valence Helix disclosed a 10.99% passive stake in Leap Therapeutics. The stake represents just under 2.6M shares. The Reporting Persons do not have any plans or proposals that relate or would result in extraordinary corporate transactions, material change in the present capitalization or dividend policy, or any other material change in the issuer's business or corporate structure.

Mid Penn Bank, subsidiary of Mid Penn Bancorp, Inc. is seeking regulatory approval to relocate its branch in Lower Paxton Township, Dauphin County, from 5500 Allentown Boulevard to 5049 Jonestown Road. The bank recently submitted an application to the Pennsylvania Department of Banking and Securities and to the Federal Deposit Insurance Corporation. Customers will be provided the amenities of a full-service branch in a more accessible location.

Regeneron Pharmaceuticals, Inc. (REGN) announced two important legal developments invalidating Immunex patents with functional claims to antibodies that target human interleukin-4 receptors. Earlier today, the Opposition Division of the European Patent Office revoked Immunex's European Patent No. 2,990,420 in its entirety because the claims were invalid for insufficiency of disclosure. This follows a decision yesterday by the Patent Trial and Appeal Board of the U.S. Patent & Trademark Office to invalidate all 17 claims of Immunex's U.S. Patent No. 8,679,487 as obvious. These decisions are subject to appeal by Immunex. The patents in question are owned by Immunex Corporation, which is wholly-owned by Amgen (AMGN). "We applaud decisions by the U.S. and European patent offices this week, which invalidate Immunex's functional patent claims to antibodies that target human IL-4 receptors," said Joseph LaRosa, Executive Vice President, General Counsel and Secretary, Regeneron. "It is our position that Immunex's functional claims unfairly attempt to claim ownership far beyond the molecules developed, and stifle innovation within the broader scientific community."

In a regulatory filing, UPS CFO Richard Peretz disclosed a February 13th sale of 9,112 shares of common stock at an average price of $111.18. The transaction size was $1.01M.

The dividend is payable March 12, 2019 to shareowners of record on Feb. 26, 2019.